PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10617910-0	2000	Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits.	iganidipine	47-58	endothelin-1	Oryctolagus cuniculus	137-149	
10617910-1	2000	PURPOSE: To investigate the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker, on impairment of the ocular circulation caused by endothelin-1 (ET-1), we examined modification of the effect of ET-1 on visual-evoked potential (VEP) in albino rabbits.	iganidipine	46-57	endothelin-1	Oryctolagus cuniculus	167-179	
10617910-1	2000	PURPOSE: To investigate the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker, on impairment of the ocular circulation caused by endothelin-1 (ET-1), we examined modification of the effect of ET-1 on visual-evoked potential (VEP) in albino rabbits.	iganidipine	46-57	endothelin-1	Oryctolagus cuniculus	181-185	
10617910-3	2000	Then modification of the effect of ET-1 on the VEP by iganidipine was examined.	iganidipine	54-65	endothelin-1	Oryctolagus cuniculus	35-39	
10617910-4	2000	One hour after the topical instillation of 0.1% iganidipine (20 microl) or its vehicle, 10 pmol of ET-1 was injected into the vitreous in rabbits.	iganidipine	48-59	endothelin-1	Oryctolagus cuniculus	99-103	
10617910-7	2000	Topical administration of 0.1% iganidipine significantly suppressed the reduction of VEP amplitude for the entire 2-hour monitoring period after intravitreal injection of 10 pmol ET-1.	iganidipine	31-42	endothelin-1	Oryctolagus cuniculus	179-183	
10617910-9	2000	CONCLUSIONS: Iganidipine eyedrops may be useful for the treatment of ischemic retinal and optic nerve disorders related to abnormal ET-1 production for the maintenance of visual function.	iganidipine	13-24	endothelin-1	Oryctolagus cuniculus	132-136